

World Journal of Gastroenterology®

Volume 16 Number 47
December 21, 2010



Published by Baishideng Publishing Group Co., Limited,
Room 1701, 17/F, Henan Building,
No. 90 Jaffe Road, Wanchai, Hong Kong, China
Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

ISSN 1007-9327



World Journal of Gastroenterology

www.wjgnet.com

Volume 16

Number 47

Dec 21

2010



ISSN 1007-9327 (print)
ISSN 2219-2840 (online)



WJG

World Journal of Gastroenterology®

Indexed and Abstracted in:

Current Contents®/Clinical Medicine,
Science Citation Index Expanded (also
known as SciSearch®), Journal Citation
Reports®, Index Medicus, MEDLINE, PubMed,
PubMed Central, and Digital Object
Identifier. ISI, Thomson Reuters, 2009 Impact
Factor: 2.092 (33/65 Gastroenterology and
Hepatology).

Volume 16 Number 47 December 21, 2010

World J Gastroenterol
2010 December 21; 16(47): 5907-6034

Online Submissions

www.wjgnet.com/1007-9327office
www.wjgnet.com

Printed on Acid-free Paper

世界胃肠病学杂志

A Weekly Journal of Gastroenterology and Hepatology

**EDITORIAL****5907** Reverse cholesterol transport revisited*van der Velde AE***TOPIC HIGHLIGHT****5908** Reverse cholesterol transport: From classical view to new insights*van der Velde AE***5916** Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism*Hoekstra M, Van Berkel TJC, Van Eck M***5925** Ecto-F₁-ATPase: A moonlighting protein complex and an unexpected apoA-I receptor*Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E, Martinez LO***5936** Biliary cholesterol secretion: More than a simple ABC*Dijkers A, Tietge UJF***5946** A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport*Temel RE, Brown JM***5953** From blood to gut: Direct secretion of cholesterol *via* transintestinal cholesterol efflux*Vrins CLJ***5958** Thyroid hormones and thyroid hormone receptors: Effects of thyromimetics on reverse cholesterol transport*Pedrelli M, Pramfalk C, Parini P***ORIGINAL ARTICLE****5965** Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients*Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M*

- 5975 Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma

Huang JX, Xiao W, Chen WC, Lin MS, Song ZX, Chen P, Zhang YL, Li FY, Qian RY, Salminen E

BRIEF ARTICLE

- 5982 Benefit of combination β -blocker and endoscopic treatment to prevent variceal rebleeding: A meta-analysis

Funakoshi N, Ségalas-Largey F, Duny Y, Oberti F, Valats JC, Bismuth M, Daurès JP, Blanc P

- 5993 Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor

Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, Sironi S

- 6001 Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's disease

Cseh A, Vasarhelyi B, Molnar K, Szalay B, Svec P, Treszl A, Dezsofi A, Lakatos PL, Arato A, Tulassay T, Veres G

- 6010 Gastroesophageal flap valve status distinguishes clinical phenotypes of large hiatal hernia

Kaneyama H, Kaise M, Arakawa H, Arai Y, Kanazawa K, Tajiri H

- 6016 Diagnosis and surgical treatment of primary hepatic lymphoma

Yang XW, Tan WF, Yu WL, Shi S, Wang Y, Zhang YL, Zhang YJ, Wu MC

- 6020 Meta-analysis of ADH1B and ALDH2 polymorphisms and esophageal cancer risk in China

Zhang GH, Mai RQ, Huang B

- 6026 Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma

Wang W, Wang GQ, Sun XW, Chen G, Li YF, Zhang LY, Qiu HB, Huang CY, Zhan YQ, Zhou ZW

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastroenterology*

APPENDIX I Meetings
I-VI Instructions to authors

AIM AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, DOI: 10.3748) is a weekly, open-access, peer-reviewed journal supported by an editorial board of 1144 experts in gastroenterology and hepatology from 60 countries.

The major task of *WJG* is to report rapidly the most recent results in basic and clinical research on esophageal, gastrointestinal, liver, pancreas and biliary tract diseases, *Helicobacter pylori*, endoscopy and gastrointestinal surgery, including: gastroesophageal reflux disease, gastrointestinal bleeding, infection and tumors; gastric and duodenal disorders; intestinal inflammation, microflora and immunity; celiac disease, dyspepsia and nutrition; viral hepatitis, portal hypertension, liver fibrosis, liver cirrhosis, liver transplantation, and metabolic liver disease; molecular and cell biology; geriatric and pediatric gastroenterology; diagnosis and screening, imaging and advanced technology.

FLYLEAF

I-VII Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiao-Fang Liu*
Responsible Electronic Editor: *Xiao-Mei Zheng*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Lin Tian*
Proofing Editorial Office Director: *Jian-Xia Cheng*

NAME OF JOURNAL*World Journal of Gastroenterology***LAUNCH DATE**

October 1, 1995

RESPONSIBLE INSTITUTION

Department of Science and Technology of Shanxi Province

SPONSOR

Taiyuan Research and Treatment Center for Digestive Diseases, 77 Shuangta Xijie, Taiyuan 030001, Shanxi Province, China

EDITING

Editorial Board of *World Journal of Gastroenterology*, Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0039
Fax: +86-10-8538-1893
E-mail: wjg@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING

Baishideng Publishing Group Co., Limited, Room 1701, 17/F, Henan Building, No.90 Jaffe Road, Wanchai, Hong Kong, China
Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION

Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

PRINT SUBSCRIPTION

RMB 245 Yuan for each issue, RMB 11760 Yuan for one year.

ONLINE SUBSCRIPTION

One-Year Price 864.00 USD

PUBLICATION DATE

December 21, 2010

CSSN

ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

HONORARY EDITORS-IN-CHIEF

James L. Boyer, *New Haven*
Ke-Ji Chen, *Beijing*
Martin H Floch, *New Haven*
Geng-Tao Liu, *Beijing*
Emmet B Keefe, *Palo Alto*
Lein-Ray Mo, *Tainan*
Eamonn M Quigley, *Cork*
Rafiq A Sheikh, *Sacramento*
Nicholas J Talley, *Rochester*
Ming-Lung Yu, *Kaohsiung*

PRESIDENT AND EDITOR-IN-CHIEFLian-Sheng Ma, *Beijing***ACADEMIC EDITOR-IN-CHIEF**

Tauseef Ali, *Oklahoma*
Mauro Bortolotti, *Bologna*
Tarkan Karakan, *Ankara*
Weekitt Kittisupamongkol, *Bangkok*
Anastasios Koulaouzidis, *Edinburgh*
Gerd A Kullak-Ublick, *Zürich*
Bo-Rong Pan, *Xi'an*
Sylvia LF Pender, *Southampton*
Max S Petrov, *Auckland*
George Y Wu, *Farmington*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Peter Draganov, *Florida*
Hugh J Freeman, *Vancouver*
Maria Concepción Gutiérrez-Ruiz, *México*
Kazuhiro Hanazaki, *Kochi*

Akio Inui, *Kagoshima*
Kalpesh Jani, *Baroda*
Javier S Martin, *Punta del Este*
Natalia A Osna, *Omaha*
Wei Tang, *Tokyo*
Alan BR Thomson, *Edmonton*
Harry HX Xia, *Hanover*

ASSOCIATE EDITORS-IN-CHIEF

You-Yong Lu, *Beijing*
John M Luk, *Pokfulam*
Hiroshi Shimada, *Yokohama*

EDITORIAL OFFICE

Jian-Xia Cheng, Director
World Journal of Gastroenterology
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0039
Fax: +86-10-8538-1893
E-mail: wjg@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT

© 2010 Baishideng. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Baishideng. Authors are required to grant *World Journal of Gastroenterology* an exclusive license to publish.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/1007-9327/g_info_20100315215714.htm. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION<http://www.wjgnet.com/1007-9327/office>



Diagnosis and surgical treatment of primary hepatic lymphoma

Xin-Wei Yang, Wei-Feng Tan, Wen-Long Yu, Song Shi, Yi Wang, You-Lei Zhang, Yong-Jie Zhang, Meng-Chao Wu

Xin-Wei Yang, Wei-Feng Tan, Wen-Long Yu, Song Shi, Yi Wang, You-Lei Zhang, Yong-Jie Zhang, Meng-Chao Wu, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China

Author contributions: Yang XW and Tan WF performed the majority of the study and collected all the clinicopathological data; Yang XW wrote the manuscript; Yu WL, Shi S, Wang Y and Zhang YL provided analytical tools and were also involved in editing the manuscript; Zhang YJ and Wu MC designed the study; Yang XW and Tan WF contributed equally to this work.

Correspondence to: Dr. Yong-Jie Zhang, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Changhai Road 225, Shanghai 200438, China. yang16jing@163.com

Telephone: +86-21-81875263 Fax: +86-21-81875263

Received: July 14, 2010 Revised: August 30, 2010

Accepted: September 7, 2010

Published online: December 21, 2010

secondary to hepatic insufficiency. The cumulative 6-mo, 1-year, and 2-year survival rates after hepatic surgery were, respectively, 85.7%, 71.4%, and 47.6%. One patient survived for > 5 years after surgery without any signs of recurrence until latest follow-up, who received routine postoperative chemotherapy every month for 2 years and then regular follow-up. By univariate analysis, postoperative chemotherapy was a significant prognostic factor that influenced survival ($P = 0.006$).

CONCLUSION: PHL is a rare entity that is often misdiagnosed, and has a potential association with chronic hepatitis B infection. The prognosis is variable, with good response to early surgery combined with postoperative chemotherapy in strictly selected patients.

© 2010 Baishideng. All rights reserved.

Key words: Primary hepatic lymphoma; Diagnosis; Surgery; Survival

Peer reviewer: Dr. Virendra Singh, MD, DM, Additional Professor, Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

Yang XW, Tan WF, Yu WL, Shi S, Wang Y, Zhang YL, Zhang YJ, Wu MC. Diagnosis and surgical treatment of primary hepatic lymphoma. *World J Gastroenterol* 2010; 16(47): 6016-6019 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v16/i47/6016.htm> DOI: <http://dx.doi.org/10.3748/wjg.v16.i47.6016>

Abstract

AIM: To assess the benefits and limits of surgery for primary hepatic lymphoma (PHL), and probability of survival after postoperative chemotherapy.

METHODS: A retrospective analysis was undertaken to determine the results of surgical treatment of PHL over the past 8 years. Only nine patients underwent such treatment. The detailed data of diagnosis, treatment, and prognosis were carefully studied.

RESULTS: All patients were mistaken as having α -fetoprotein-negative hepatic cancer before pathological diagnosis. The mean delay time between initial symptoms and final diagnosis was 26.8 d (range: 14-47 d). Hepatitis B virus infection was noted in 33.3% of these patients. Most of the lesions were found to be restricted to a solitary hepatic mass. The surgical procedure performed was left hepatectomy in five cases, including left lateral segmentectomy in three. Right hepatectomy was performed in three cases and combined procedures in one. One patient died on the eighth day after surgery,

INTRODUCTION

Primary hepatic lymphoma (PHL) is confined to the liver with no evidence of lymphomatous involvement in the spleen, lymph nodes, bone marrow, or other lymphoid structures^[1]. PHL is a very rare malignancy, and constitutes about 0.016% of all cases of non-Hodgkin's lymphoma^[1]. Most patients are treated with chemotherapy, with some physicians employing a multimodality approach^[2]. However, the optimal therapy is still unclear and the outcomes

are uncertain. The purpose of this short report is to define the correct management of PHL with the help of nine clinical cases observed in the past 8 years.

MATERIALS AND METHODS

Patients

In view of the policy to try to resect hepatic lymphoma completely whenever possible, the charts of all patients operated upon for this condition from January 2002 to March 2010 were reviewed retrospectively. The diagnosis of PHL was defined^[3]: (1) at the time of disease presentation, the patient's symptoms were caused mainly by the liver involvement; (2) there was an absence of palpable lymphadenopathy, and no radiological evidence of distant lymphadenopathy; and (3) there was an absence of leukemic blood involvement in the peripheral blood smear. Thus, patients with splenic, lymph node, or bone marrow involvement were excluded. During this period, only nine patients met these criteria. The analyses included sex, age, information concerning PHL, the type of liver surgery performed, postoperative therapy, the associated morbidity and mortality, and overall survival. The follow-up was complete for all nine patients.

Statistical analysis

The clinicopathological factors were analyzed for prognostic significance using a Kaplan-Meier product-limit method with a log-rank test. Significance was established at $P < 0.05$. Statistical calculations were performed by a statistical analysis program package (SPSS Inc., Chicago, IL, USA).

RESULTS

Clinicopathological data

The clinicopathological characteristics of the patients are depicted in Table 1. PHL commonly presents at 51 years of age (range: 28-78 years), with a male to female ratio of 0.8:1. The most common presenting symptom is abdominal pain or discomfort, which occurs in 55.6% of patients. Clinical examination revealed the presence of palpable abdominal masses in 22.2% of cases. All patients were misdiagnosed before pathological diagnosis. The mean delay time between initial symptoms and final pathological diagnosis was 26.8 d (range: 14-47 d). Diffuse large B-cell lymphomas were the most common type of PHL (66.7% of cases). The next most common type was mucosa-associated B-cell lymphoma, found in 22.2% of cases, followed by peripheral T-cell lymphoma (11.1%).

Laboratory findings

Liver function tests, including transaminases, alkaline phosphatase, lactate dehydrogenase and bilirubin were abnormal in 33.3% of patients. As the bone marrow was not involved, blood counts were within the normal range in most patients, except for three with marked splenomegaly related to liver dysfunction. Tests for human immunodeficiency virus, hepatitis B virus (HBV), and hepa-

Table 1 Clinicopathological characteristics of patients, primary hepatic lymphoma and liver resection

Clinicopathological characteristics	Value (%)
No. of patients	9
Median age (at the time of surgery)	51.4 yr (range: 28-78 yr)
Sex	
Male	4
Female	5
Hypertension	1
Rheumatic heart disease	1
Hepatitis B infection	3 (33.3)
Hepatitis C infection	1 (11.1)
PHL	
Median diameter of PHL lesion	5.0 cm (range: 1.0-10.0 cm)
No. of PHL lesions	
Solitary	8
Multiple	1
Site of PHL lesion	
Left lobe	5
Right lobe	3
Bilobar	1
Vascular invasion	
Present	0
Absent	9
Lymph node involvement	
Present	1
Absent	8
Interruption of hepatic hilum	
Present	9 (14.0 ± 4.2 min, range: 8-20 min)
Absent	0
Type of liver resection	
Left hepatectomy	5
Right hepatectomy	3
Combined procedures	1
Length of operation	110 ± 59 (range: 50-255 min)
Blood loss of operation	211 ± 74 (range: 100-300 mL)
Adjuvant regional therapy	
Present	5 (55.6)
Absent	4 (44.4)

PHL: Primary hepatic lymphoma.

titis C virus (HCV) were also carried out. In all patients, α -fetoprotein (AFP) and carcinoembryonic antigen were not significantly elevated. Hypercalcemia and coagulation abnormalities were not found in any of our patients. HBV infection was noted in 33.3% of these patients and hepatitis C in 11.1%.

Imaging studies

The most common presentation was a solitary lesion, which occurred in about 77.8% of cases, followed by multiple lesions in about 22.2% of patients. Ultrasound was performed in all the patients and usually demonstrated hypoechoic lesions to the surrounding normal liver parenchyma in 88.9% of cases.

On computed tomography, PHL lesions usually appear as hypoattenuating lesions, which might have a central area of low intensity that indicates necrosis (Figure 1A). Following the administration of intravenous contrast agent, PHL lesions might show slight enhancement (Figure 1B). Most magnetic resonance imaging (MRI) findings in PHL were described as hypointense on T1-weighted images, and hyperintense on T2-weighted images in our patients.




Figure 1 The preoperative imaging and surgical specimen in primary hepatic lymphoma. A: By computed tomography, primary hepatic lymphoma (PHL) appeared as a solitary hypoattenuating lesion with a central area of low intensity; B: PHL lesion was slightly enhanced following the administration of intravenous contrast agent; C: Pathological features revealed that the PHL lesion was an encapsulated, hypovascular tumor with central necrosis.

Operative details and perioperative outcome

Liver resection was performed in all cases. In eight patients, the resection was classified as curative, whereas one patient had palliative resection with a portal lymph-node-positive biopsy. The distribution of surgical procedures was left hepatectomy in five patients (55.6%), right hepatectomy in three (33.3%), and combined procedure in one (11.1%). In the postoperative course, one patient died on the eighth day after surgery, secondary to hepatic insufficiency. Postoperative chemotherapy was administered to five patients.

Survival and prognostic factors

The cumulative 6-mo, 1-year and 2-year survival rate was 77.8%, 66.7%, and 55.6%, respectively, with a median survival of 23 mo. One patient was also alive and tumor-




Figure 2 Survival among patients undergoing hepatic resection for primary hepatic lymphoma, with or without postoperative chemotherapy, and the overall cumulative survival of all patients (except for one who died perioperatively). ^b $P < 0.01$ vs hepatic resection for primary hepatic lymphoma with postoperative chemotherapy (log rank test).

free for > 5 years after resection. Among the factors considered, postoperative chemotherapy ($P = 0.006$) was the only significant prognostic factor for survival (Figure 2).

DISCUSSION

We suggest that our patients had PHL because we found only liver tumor and no lymphadenopathy or bone marrow lesions. Although the liver contains lymphoid tissue, host factors can make the liver a poor environment for the development of malignant lymphoma^[4]. Therefore, PHL is rare. In our study, PHL in men was less frequent than in women, which did not accord with the previously reported trend towards male predominance^[1-5].

The etiology of PHL is unknown, although several possible factors such as hepatitis, cirrhosis, and immunosuppressive drugs have been proposed^[3]. There appeared to be a strong association between PHL and HBV in our patients. Hepatitis B was found in 33.3% of patients. In contrast, the prevalence of hepatitis C was very low, with only one patient having the infection. However, some authors have revealed a variety of possible associations between PHL and chronic HCV infection^[6-8].

Conflicting theories exist on the association of HBV infection and PHL^[3,9-11]. Aozasa *et al*^[9] have reported a 20% prevalence of hepatitis B surface antigen positivity in a series of 69 patients with PHL, in which 52 patients were from western countries and 17 from Japan. Chronic antigenic stimulation by HBV has been postulated to play a role in the development of PHL^[10]. Based on all these data, it is likely that some association between PHL and HBV does in fact exist. However, the high prevalence of HBV infection in the present study perhaps corresponded to the high HBV seropositivity in China of 10% in the general population^[12].

Although it remains uncertain to what extent HBV contributes to the development of PHL, a host environment with impaired immunity might play an important role^[6,7,13]. Therefore, we hypothesize that chronic HBV infection, as with our three patients, could have impaired

host immunity, which subsequently led to accelerated development of PHL. If this hypothesis is confirmed, suppression from HBV infection or from complications related to chronic viral infections could be crucial steps in preventing carcinogenesis of PHL.

Due to the rarity of this disease entity, the non-specific clinical presentation, and laboratory and radiological features, PHL can be confused with focal nodular hyperplasia, primary hepatic tumors, carcinoma with hepatic metastases, and systemic lymphoma with secondary hepatic involvement^[10]. In the present study, all patients were mistaken as having AFP-negative hepatic cancer before pathological diagnosis. We retrospectively performed imaging studies to discriminate between these possibilities. As in our patients, most PHL is usually hypoechoic by sonography and shows hypointensity on T1-weighted and hyperintensity on T2-weighted MRI.

The optimal therapy for PHL is still unclear and the outcomes are uncertain^[5]. Most patients with PHL present with poor prognostic features. One large review of 72 patients has shown the median survival to be 15.3 mo (range: 0-123.6 mo)^[14]. In our study, the median overall survival for all nine patients was 23 mo. These results are better than those previously reported and could have been due to strict patient selection and the use of postoperative chemotherapy in most patients.

Our univariate analysis revealed that postoperative chemotherapy was the only significant prognostic factor that influenced survival. In a previous study, one patient treated with surgery followed by chemotherapy and radiation was reported to be alive at 5 years following initial diagnosis^[2]. Page *et al.*^[15] have stratified several pretreatment risk factors after a retrospective cohort review. Lei has proposed that, in patients with localized disease, surgery followed by adjuvant chemotherapy should be considered to prevent disease recurrence^[3]. Therefore, we advise that good prognosis of PHL can be obtained by early surgery combined with chemotherapy in strictly selected patients.

The primary limitation of this study was the small sample size and its retrospective nature, even though this study population represents a relatively large sample in surgical management of PHL in one single center. A larger prospective series could enable us to draw more substantive conclusions with regard to the roles of postoperative chemotherapy and HBV infection in the surgical setting of PHL.

COMMENTS

Background

Primary hepatic lymphoma (PHL) is a rare malignancy. The rarity of the disease

causes problems in diagnosis and management. The optimal therapy is still unclear and the outcomes are uncertain.

Peer review

The authors reported their experience of surgical management of PHL. Satisfactory survival can be achieved by early surgery combined with postoperative chemotherapy in strictly selected patients.

REFERENCES

- 1 Agmon-Levin N, Berger I, Shtalrid M, Schlanger H, Stoecker ZM. Primary hepatic lymphoma: a case report and review of the literature. *Age Ageing* 2004; **33**: 637-640
- 2 Noronha V, Shafi NQ, Obando JA, Kummur S. Primary non-Hodgkin's lymphoma of the liver. *Crit Rev Oncol Hematol* 2005; **53**: 199-207
- 3 Lei KI. Primary non-Hodgkin's lymphoma of the liver. *Leuk Lymphoma* 1998; **29**: 293-299
- 4 Maes M, Depardieu C, Dargent JL, Hermans M, Verhaeghe JL, Delabie J, Pittaluga S, Troufléau P, Verhest A, De Wolf-Peeters C. Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases. *J Hepatol* 1997; **27**: 922-927
- 5 Bronowicki JP, Bineau C, Feugier P, Hermine O, Brousse N, Oberti F, Rousselet MC, Dharancy S, Gaulard P, Flejou JF, Cazals-Hatem D, Labouyrie E. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. *Hepatology* 2003; **37**: 781-787
- 6 Chen HW, Sheu JC, Lin WC, Tsang YM, Liu KL. Primary liver lymphoma in a patient with chronic hepatitis C. *J Formos Med Assoc* 2006; **105**: 242-246
- 7 Hsiao HH, Liu YC, Hsu JF, Huang CF, Yang SF, Lin SF. Primary liver lymphoma with hypercalcemia: a case report. *Kaohsiung J Med Sci* 2009; **25**: 141-144
- 8 Kim JH, Kim HY, Kang I, Kim YB, Park CK, Yoo JY, Kim ST. A case of primary hepatic lymphoma with hepatitis C liver cirrhosis. *Am J Gastroenterol* 2000; **95**: 2377-2380
- 9 Aozasa K, Mishima K, Ohsawa M. Primary malignant lymphoma of the liver. *Leuk Lymphoma* 1993; **10**: 353-357
- 10 Ohsawa M, Tomita Y, Hashimoto M, Kanno H, Aozasa K. Hepatitis C viral genome in a subset of primary hepatic lymphomas. *Mod Pathol* 1998; **11**: 471-478
- 11 Masood A, Kairouz S, Hudhud KH, Hegazi AZ, Banu A, Gupta NC. Primary non-Hodgkin lymphoma of liver. *Curr Oncol* 2009; **16**: 74-77
- 12 Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnain SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. *J Gastroenterol Hepatol* 2000; **15**: 1356-1361
- 13 Wu SJ, Hung CC, Chen CH, Tien HF. Primary effusion lymphoma in three patients with chronic hepatitis B infection. *J Clin Virol* 2009; **44**: 81-83
- 14 Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. *Eur J Surg* 1999; **165**: 725-729
- 15 Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, Sanz-Rodriguez C, Cabanillas F. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. *Cancer* 2001; **92**: 2023-2029

S- Editor Sun H L- Editor Kerr C E- Editor Lin YP